Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 1;208(5):1170–1179. doi: 10.4049/jimmunol.2100912

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by The American Association of Immunologists, Inc.

This article is distributed under The American Association of Immunologists, Inc., Reuse Terms and Conditions for Author Choice articles.

PMC Copyright notice

FIGURE 5. — LukED targets mature CD56^dim NK cells mostly independent of CCR5. (A) Representative flow cytometry plots and combined donor data of the percentage and absolute count of CD56^bright and CD56^dim NK cells on LukED treatment for 4 h (n = 6). LukED is used at 5 µg/ml throughout the figure. (B) Percentage of depletion of CD56^bright and CD56^dim NK cells on LukED treatment (n = 6). Representative flow cytometry plots (C) and combined data (D) of the expression of CXCR1, CXCR2, and CCR5 on CD56^bright and CD56^dim NK cells (n = 6). (E) Representative flow cytometry plots and combined data of the expression of CD27 and NKG2A on CD56^bright and the expression of KIRD2L1, CD57, Perforin, and CD16 on CD56^dim NK cells with or without LukED treatment (n = 6). (F) Combined data of the percentage of coexpression of the indicated markers on CD56^bright (left) and CD56^dim (right) NK cells with or without LukED exposure (n = 6). The Wilcoxon signed-rank test was performed to determine significance. The lines and error bars represent mean and SE. *p < 0.05.